Company Overview and News

 
ICICI case: BBB member’s Avista stint under scanner

2018-04-17 freepressjournal.in
New Delhi : The finance ministry is looking at the professional assistance provided by newly-appointed Banks Board Bureau (BBB) member P Pradeep Kumar during his stint at Avista Advisory Group, which is caught in the controversy involving ICICI Bank and Videocon Group, sources said.
Upvote Downvote

 
Jaiprakash Power Ventures Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Doubts linger on Rajiv Kochhar role in ICICI Bank loan mess

2018-04-03 freepressjournal.in
Mumbai : Media is thick with reports about investigations being undertaken about financial affairs at ICICI Bank. It is now the turn of the Central Bureau of Investigation (CBI) to begin questioning of not just ICICI Bank officials but also the Kochhars — Chanda and her husband, Deepak. But there is one more Kochhar whose activities in the financial markets may be worth investigating. The person is Rajiv Kochhar, Deepak Kochhar’s brother.
Upvote Downvote

 
Jaiprakash Power Ventures Q3 loss swells to Rs 194 crore

2018-02-08 moneycontrol
Jaiprakash Power Ventures Ltd (JPVL) said on Thursday that its standalone net loss widened to Rs 194.41 crore in the December quarter of the current fiscal.
Upvote Downvote

 
Jaiprakash Power Ventures Limited - Financial Result Updates

2018-02-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
JSW Energy Q3 net jumps two-fold to Rs 505 mn on lower effective tax rate

2018-02-06 business-standard
Sajjan Jindal-led JSW Energy on Tuesday reported a nearly two-fold increase in net profit for the quarter ended December 31 at Rs 505.5 million mainly on the back of improved revenues, decline in finance cost and lower effective tax rate. The company had reported a net profit of Rs 179.6 million in the corresponding quarter last fiscal. Its total revenues for the October-December period grew 6.46 per cent to Rs 20.
Upvote Downvote

 
JSW Energy Q3 profit jumps two fold to Rs50.55 crore

2018-02-06 livemint
Mumbai: Sajjan Jindal-led JSW Energy on Tuesday reported a nearly two-fold increase in net profit for the quarter ended 31 December at Rs50.55 crore mainly on the back of improved revenues, decline in finance cost and lower effective tax rate.
Upvote Downvote

 
JSW Energy Q3 FY18 PAT jumps two fold to Rs 50.55 crore

2018-02-06 moneycontrol
Sajjan Jindal-led JSW Energy reported a nearly two-fold increase in net profit for the quarter ended December 31 at Rs 50.55 crore mainly on the back of improved revenues, decline in finance cost and lower effective tax rate.
Upvote Downvote

 
Sensex, Nifty end rangebound session at new closing high; Coal India rises 6%

2018-01-09 moneycontrol
The market continued its buoyant mood on Tuesday as benchmark indices ended rangebound session at new closing high. The midcaps, however, snapped a four-day winning streak as investors await corporate earnings.
Upvote Downvote

 
RBI deadline for 2nd NPA list: Banks still in process of filing 25 of 28 accounts in NCLT

2018-01-02 moneycontrol
While the NPA clean-up exercise continues, the cumbersome out-of-court resolution processes to be completed before December 13 delayed the filings by a few days.
Upvote Downvote

 
JSW Energy drops plan to buy Jaiprakash’s Bina power plant

2018-01-01 thehindubusinessline
JSW Energy has terminated talks with Jaiprakash Power Ventures to acquire its 500 MW thermal power plant at Bina in Madhya Pradesh as the seller could not meet certain criteria mentioned in the agreement.
Upvote Downvote

 
JSW Energy shelves plan to buy 500MW Bina plant

2018-01-01 livemint
Mumbai: Sajjan Jindal’s JSW Energy has called off a plan to acquire the 500 megawatt (MW) Bina thermal power plant of Jaiprakash Power Ventures, the company said on Monday.
Upvote Downvote

 
JSW Energy cancels Rs 2,700 cr purchase of JPVL Bina plant over deal delay

2018-01-01 business-standard
Sajjan Jindal-led JSW Energy on Monday said its deal with Jaiprakash Power Ventures to acquire 500 MW Bina thermal power plant is terminated following the lapse of time for completion of the transaction yesterday. "With the elapsing of the Long Stop Date, the proposed acquisition of the Bina project stands terminated," JSW Energy said in BSE filing today.
Upvote Downvote

 
Jaiprakash Power Ventures Limited - Updates

2018-01-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...